Entera Bio Ltd. (ENTX) stock
ENTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 6/30
$3.00−0.02 (-0.66%)
Close on Nov 17, 2026Market cap $519.43MP/E –Yield –
Entera Bio gross margin
Gross margin is gross profit as a percentage of revenue.
Entera Bio's gross margin for the twelve months ending Dec 31, 2025 was 0.0%. For fiscal 2025 it was 0.0%, against 5.0% the year before. The highest annual figure on record is 34.7% in fiscal 2021.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0.0% | −5.0 |
| FY2024 | Dec 31, 2024 | 5.0% | −19.7 |
| FY2022 | Dec 31, 2022 | 24.6% | −10.0 |
| FY2021 | Dec 31, 2021 | 34.7% | +16.9 |
| FY2020 | Dec 31, 2020 | 17.8% | +6.8 |
| FY2019 | Dec 31, 2019 | 11.0% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q1 FY2025 | Mar 31, 2025 | 0.0% | −42.9 |
| Q4 FY2024 | Dec 31, 2024 | 0.0% | −25.0 |
| Q3 FY2024 | Sep 30, 2024 | 0.0% | −25.0 |
| Q2 FY2024 | Jun 30, 2024 | 15.8% | −4.8 |
| Q4 FY2022 | Dec 31, 2022 | 42.9% | +25.3 |
| Q3 FY2022 | Sep 30, 2022 | 25.0% | −28.6 |
| Q2 FY2022 | Jun 30, 2022 | 25.0% | +15.8 |
| Q1 FY2022 | Mar 31, 2022 | 20.6% | −32.9 |
| Q4 FY2021 | Dec 31, 2021 | 17.6% | −22.8 |
| Q3 FY2021 | Sep 30, 2021 | 53.6% | +37.4 |
| Q2 FY2021 | Jun 30, 2021 | 9.2% | – |
| Q1 FY2021 | Mar 31, 2021 | 53.5% | – |
| Q2 FY2020 | Jun 30, 2020 | 40.4% | – |
| Q2 FY2019 | Jun 30, 2019 | 16.2% | – |
See a number that looks wrong?